Literature DB >> 16369561

Breaking down the barriers to cancer immunotherapy.

Ellen Puré1, James P Allison, Robert D Schreiber.   

Abstract

Emerging insights into the mechanisms of activation and negative regulation of innate and adaptive immune cells are providing new opportunities for the development of safe and effective cancer vaccines.

Entities:  

Mesh：

Year:  2005        PMID： 16369561     DOI： 10.1038/ni1205-1207

Source DB:  PubMed          Journal:  Nat Immunol        ISSN： 1529-2908            Impact factor:   25.606


  13 in total

1.  Cytotoxic T lymphocyte-associated antigen-4 +49A>G polymorphism and the risk of non-small cell lung cancer in a Chinese population.

Authors:  Hui-Ning Liu; Jian-Ling Su; Shao-Hui Zhou; Li-Jun Liu; Peng Qie
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 2.  Immunosuppressive strategies that are mediated by tumor cells.

Authors:  Gabriel A Rabinovich; Dmitry Gabrilovich; Eduardo M Sotomayor
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

3.  MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.

Authors:  P Mukherjee; L B Pathangey; J B Bradley; T L Tinder; G D Basu; E T Akporiaye; S J Gendler
Journal:  Vaccine       Date:  2006-11-16       Impact factor: 3.641

Review 4.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

5.  Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines.

Authors:  Cory L Ahonen; Anna Wasiuk; Shinichiro Fuse; Mary Jo Turk; Marc S Ernstoff; Arief A Suriawinata; James D Gorham; Ross M Kedl; Edward J Usherwood; Randolph J Noelle
Journal:  Blood       Date:  2008-01-17       Impact factor: 22.113

6.  Meta-analysis of the cytotoxic T-lymphocyte antigen 4 gene +6230G/A polymorphism and cancer risk.

Authors:  H-Y Zhao; H-X Duan; Y Gu
Journal:  Clin Transl Oncol       Date:  2014-02-04       Impact factor: 3.405

Review 7.  Dendritic cells: a critical player in cancer therapy?

Authors:  Anna Karolina Palucka; Hideki Ueno; Joseph Fay; Jacques Banchereau
Journal:  J Immunother       Date:  2008 Nov-Dec       Impact factor: 4.456

8.  Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.

Authors:  Marianna Sabatino; Seunghee Kim-Schulze; Monica C Panelli; David Stroncek; Ena Wang; Bret Taback; Dae Won Kim; Gail Deraffele; Zoltan Pos; Francesco M Marincola; Howard L Kaufman
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

9.  Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis.

Authors:  Craig M Brackett; Bojidar Kojouharov; Jean Veith; Kellee F Greene; Lyudmila G Burdelya; Sandra O Gollnick; Scott I Abrams; Andrei V Gudkov
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-01       Impact factor: 11.205

Review 10.  Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy.

Authors:  Neale Hanke; Darya Alizadeh; Emmanuel Katsanis; Nicolas Larmonier
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.